THAR Profile
Tharimmune, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for rare, inflammatory, and oncologic diseases. The company focuses on harnessing advanced immuno-oncology approaches to address unmet medical needs in these challenging areas. Its pre-clinical pipeline features several promising candidates, including TH104, which targets liver-related and pruritogenic inflammatory conditions. TH104 is designed to address inflammatory diseases where traditional treatments have limited efficacy.
In addition to TH104, Tharimmune is advancing TH3215 and TH0059, both of which are aimed at treating various solid tumors. These product candidates represent the company's commitment to tackling complex cancer types with novel therapeutic strategies. Another key asset in its pipeline is TH1940, which specifically targets programmed cell death protein 1 (PD-1), a critical checkpoint protein involved in immune evasion by tumors. This approach aims to enhance the immune system's ability to recognize and attack cancer cells.
Tharimmune has established a research collaboration and product license agreement with Minotaur Therapeutics, Inc., focusing on the development of proprietary targeted biologics. This partnership underscores Tharimmune's strategy to leverage external expertise and resources to accelerate the advancement of its therapeutic candidates. The collaboration aims to bolster the company's research capabilities and expand its portfolio of innovative treatments.
Originally known as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 to better reflect its strategic focus and evolving business model. Incorporated in 2017 and headquartered in Bridgewater, New Jersey, Tharimmune continues to pursue cutting-edge solutions in the biotechnology field, driven by its commitment to improving patient outcomes through breakthrough therapies. The company's dynamic approach and robust pipeline position it at the forefront of addressing significant medical challenges in immuno-oncology and beyond.
|
